Current therapy of acute uncomplicated cystitis

International Journal of Urology

Volumn 17, Issue 5, 2010, Pages 450-456

  Yamamoto, Shingo ^a   Higuchi, Yoshihide ^a   Nojima, Michio ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

3 day therapy; Acute uncomplicated cystitis; Fluoroquinolone; Guidelines; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALEXIN; CEFAZOLIN; CEFDINIR; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CIPROXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FLEROXACIN; FOSFOMYCIN TROMETAMOL; GATIFLOXACIN; GENTAMICIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SULPERAZON; TAZOBACTAM; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE UNCOMPLICATED CYSTITIS; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTITIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ESCHERICHIA COLI; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT DURATION; URINARY TRACT INFECTION;

ACUTE DISEASE; CYSTITIS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 77951282714     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02500.x     Document Type: Review

References (40)

1. Hooton TM, Scholes D, Hughes JP et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 1996 335 : 468 474.
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 2002 113 (Suppl 1A 5S 13S.
3. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. 1999 29 : 745 758.
4. Gupta K, Stamm WE. Outcomes associated with trimethoprim/ sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. Int. J. Antimicrob. Agents 2002 19 : 554 556.
5. Naber KG, Bergman B, Bishop MC et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur. Urol. 2001 40 : 576 588.
6. Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol. Clin. North Am. 2008 35 : 1 12.
7. Tice AD. Short-course therapy of acute cystitis: a brief review of therapeutic strategies. J. Antimicrob. Chemother. 1999 43 (Suppl A 85 93.
8. Hooton TM, Johnson C, Winter C et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob. Agents Chemother. 1991 35 : 1479 1483.
9. Naber KG, Allin DM, Clarysse L et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 2004 23 : 596 605.
10. Kahlmeter G, ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J. Antimicrob. Chemother. 2003 51 : 69 76.
11. Hooton TM. The current management strategies for community-acquired urinary tract infection. Infect. Dis. Clin. North Am. 2003 17 : 303 332.
12. Yamamoto S, Akiyama K, Yoshimoto T et al. Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis. J. Infect. Chemother. 2009 15 : 104 107.
13. Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J. Urol. 1997 157 : 1127 1129.
14. Mitsumori K, Terai A, Yamamoto S, Yoshida O. Virulence characteristics and DNA fingerprints of Escherichia coli isolated from women with acute uncomplicated pyelonephritis. J. Urol. 1997 158 : 2329 2332.
15. Garofalo CK, Hooton TM, Martin SM et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect. Immun. 2007 75 : 52 60.
16. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J. Infect. Dis. 2000 182 : 1177 1182.
17. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 1993 329 : 753 756.
18. Jackson SL, Boyko EJ, Scholes D, Abraham L, Gupta K, Fihn SD. Predictors of urinary tract infection after menopause: a prospective study. Am. J. Med. 2004 117 : 903 911.
19. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin. Infect. Dis. 2001 33 : 615 621.
20. Perfetto EM, Gondek K. Escherichia coli resistance in uncomplicated urinary tract infection: a model for determining when to change first-line empirical antibiotic choice. Manag. Care Interface 2002 15 : 35 42.
21. De Francesco MA, Ravizzola G, Peroni L, Negrini R, Manca N. Urinary tract infections in Brescia, Italy: etiology of uropathogens and antimicrobial resistance of common uropathogens. Med. Sci. Monit. 2007 13 : BR136 44.
22. Daza R, Gutiérrez J, Piédrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int. J. Antimicrob. Agents 2001 18 : 211 215.
23. Sader HS, Biedenbach DJ, Streit JM, Jones RN. Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. Int. J. Antimicrob. Agents 2005 25 : 89 92.
24. Bean DC, Krahe D, Wareham DW. Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006. Ann. Clin. Microbiol. Antimicrob. 2008 7 : 13.
25. Ling TK, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM. Multicenter antimicrobial susceptibility survey of gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China. Antimicrob. Agents Chemother. 2006 50 : 374 378.
26. Raz R, Chazan B, Kennes Y et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 2002 34 : 1165 1169.
27. McNulty CA, Richards J, Livermore DM et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J. Antimicrob. Chemother. 2006 58 : 1000 1008.
28. Hames L, Rice CE. Antimicrobial resistance of urinary tract isolates in acute uncomplicated cystitis among college-aged women: choosing a first-line therapy. J. Am. Coll. Health 2007 56 : 153 156.
29. Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk factors for rimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob. Agents Chemother. 2008 52 : 846 851.
30. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J. Clin. Microbiol. 2008 46 : 2605 2612.
31. Muratani T, Matsumoto T. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int. J. Antimicrob. Agents 2006 28 (Suppl 1 S10 13.
32. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int. J. Antimicrob. Agents 2008 31 (Suppl 1 S15 18.
33. Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J. Antimicrob. Chemother. 2005 56 : 914 918.
34. Katchman EA, Milo G, Paul M, Christiaens T, Baerheim A, Leibovici L. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am. J. Med. 2005 118 : 1196 1207.
35. Rafalsky V, Andreeva I, Rjabkova E. Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst. Rev. 2006 3 CD003597.
36. Nicolle LE. Short-term therapy for urinary tract infection: success and failure. Int. J. Antimicrob. Agents 2008 31 (Suppl 1 S40 5.
37. Wagenlehner FM, Naber KG. Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles. Expert. Rev. Anti. Infect. Ther. 2004 2 : 923 931.
38. Takahashi A, Muratani T, Yasuda M et al. Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns. J. Clin. Microbiol. 2009 47 : 791 795.
39. Olofsson SK, Marcusson LL, Strömbäck A, Hughes D, Cars O. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J. Antimicrob. Chemother. 2007 60 : 795 801.
40. Zhang YY, Huang HH, Ren ZY et al. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. J. Infect. Chemother. 2009 15 : 301 311.